Pavla Krotka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pavla Krotka has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Marta Bofill Roig
Department of Statistics and Operations Research and Institute for Research and Innovation in Health (IRIS) Universitat Politécnica de Catalunya – BarcelonaTech (UPC) Barcelona Spain
5 shared publications Dominic Magirr
2 shared publicationsKatharina Hees
2 shared publicationsMartin Posch
Center for Medical Data Science Medical University of Vienna Vienna Austria
2 shared publicationsPeter Jacko
2 shared publications- Dario Zocholl
Charité University Medicine of Berlin, Institute of Biometry and Clinical Epidemiology, Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 18 May 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (10-12) , e70585
On the Inclusion of Non‐Concurrent Controls in Platform Trials With an Interim Analysis
The analysis of platform trials can be enhanced by utilizing non‐concurrent controls. Since including this data might also introduce bias in the treatment effect estimators if time trends are present, methods for incorporating non‐concurrent controls adjusting for time have been proposed. However, so far their behavior has not been systematically investigated in platform trials that include interim analyses. To evaluate the impact of an interim analysis in trials utilizing non‐concurrent controls, we consider a platform trial featuring two experimental arms and a shared control, with the second experimental arm entering later. We focus on a frequentist regression model that uses non‐concurrent controls to estimate the treatment effect of the second arm and adjusts for time using a step function to account for temporal changes. We show that performing an interim analysis in Arm 1 may introduce bias in the point estimation of the effect in Arm 2, if the regression model is used without adjustment, and investigate how the marginal bias and bias conditional on the first arm continuing after the interim depend on different trial design parameters. Moreover, we propose a new estimator of the treatment effect in Arm 2, aiming to eliminate the bias introduced by both the interim analysis in Arm 1 and the time trends, and evaluate its performance in a simulation study. The newly proposed estimator is shown to substantially reduce the bias and type I error rate inflation while leading to power gains compared to an analysis using only concurrent controls.
- 18 May 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (10-12) , e70585
Open AccessOn the Inclusion of Non‐Concurrent Controls in Platform Trials With an Interim Analysis
The analysis of platform trials can be enhanced by utilizing non‐concurrent controls. Since including this data might also introduce bias in the treatment effect estimators if time trends are present, methods for incorporating non‐concurrent controls adjusting for time have been proposed. However, so far their behavior has not been systematically investigated in platform trials that include interim analyses. To evaluate the impact of an interim analysis in trials utilizing non‐concurrent controls, we consider a platform trial featuring two experimental arms and a shared control, with the second experimental arm entering later. We focus on a frequentist regression model that uses non‐concurrent controls to estimate the treatment effect of the second arm and adjusts for time using a step function to account for temporal changes. We show that performing an interim analysis in Arm 1 may introduce bias in the point estimation of the effect in Arm 2, if the regression model is used without adjustment, and investigate how the marginal bias and bias conditional on the first arm continuing after the interim depend on different trial design parameters. Moreover, we propose a new estimator of the treatment effect in Arm 2, aiming to eliminate the bias introduced by both the interim analysis in Arm 1 and the time trends, and evaluate its performance in a simulation study. The newly proposed estimator is shown to substantially reduce the bias and type I error rate inflation while leading to power gains compared to an analysis using only concurrent controls.
- Open Access
- 10 June 2025
- Published by Wiley in Biometrical Journal
- Vol. 67 (3) , e70059
Statistical Modeling to Adjust for Time Trends in Adaptive Platform Trials Utilizing Non‐Concurrent Controls
Utilizing non‐concurrent control (NCC) data in the analysis of late‐entering arms in platform trials has recently received considerable attention. While incorporating NCC can lead to increased power and lower sample sizes, it might introduce bias to the effect estimators if temporal drifts are present. Aiming to mitigate this potential bias, we propose various frequentist model‐based approaches that leverage the NCC, while adjusting for time. One of the currently available models incorporates time as a categorical fixed effect, separating the trial duration into periods, defined as time intervals bounded by any arm entering or leaving the platform. In this work, we propose two extensions of this model. First, we consider an alternative definition of time by dividing the trial into fixed‐length calendar time intervals. Second, we propose alternative model‐based time adjustments. Specifically, we investigate adjusting for random effects and employing splines to model time with a polynomial function. We evaluate the performance of the proposed approaches in a simulation study and illustrate their use through a case study. We show that adjusting for time via a spline function controls the type I error in trials with a sufficiently smooth time trend pattern and may lead to power gains compared to the standard fixed effect model. However, the fixed effect model with period adjustment is the most robust model for arbitrary time trends, provided that the trend is equal across all arms. Especially, in trials with sudden changes in the time trend, the period‐adjustment model is preferred if NCCs are included.
- 10 June 2025
- Published by Wiley in Biometrical Journal
- Vol. 67 (3) , e70059
Open AccessStatistical Modeling to Adjust for Time Trends in Adaptive Platform Trials Utilizing Non‐Concurrent Controls
Utilizing non‐concurrent control (NCC) data in the analysis of late‐entering arms in platform trials has recently received considerable attention. While incorporating NCC can lead to increased power and lower sample sizes, it might introduce bias to the effect estimators if temporal drifts are present. Aiming to mitigate this potential bias, we propose various frequentist model‐based approaches that leverage the NCC, while adjusting for time. One of the currently available models incorporates time as a categorical fixed effect, separating the trial duration into periods, defined as time intervals bounded by any arm entering or leaving the platform. In this work, we propose two extensions of this model. First, we consider an alternative definition of time by dividing the trial into fixed‐length calendar time intervals. Second, we propose alternative model‐based time adjustments. Specifically, we investigate adjusting for random effects and employing splines to model time with a polynomial function. We evaluate the performance of the proposed approaches in a simulation study and illustrate their use through a case study. We show that adjusting for time via a spline function controls the type I error in trials with a sufficiently smooth time trend pattern and may lead to power gains compared to the standard fixed effect model. However, the fixed effect model with period adjustment is the most robust model for arbitrary time trends, provided that the trend is equal across all arms. Especially, in trials with sudden changes in the time trend, the period‐adjustment model is preferred if NCCs are included.
- Open Access
- 17 January 2025
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 25 (1) , 1-11
Why and how should we simulate platform trials? Learnings from EU-PEARL
Platform trials are innovative clinical trials governed by a master protocol that allows for the evaluation of multiple investigational treatments that enter and leave the trial over time. Interest in platform trials has been steadily increasing over the last decade. Due to their highly adaptive nature, platform trials provide sufficient flexibility to customize important trial design aspects to the requirements of both the specific disease under investigation and the different stakeholders. The flexibility of platform trials, however, comes with complexities when designing such trials. In the past, we reviewed existing software for simulating clinical trials and found that none of them were suitable for simulating platform trials as they do not accommodate the design features and flexibility inherent to platform trials, such as staggered entry of treatments over time. We argued that simulation studies are crucial for the design of efficient platform trials. We developed and proposed an iterative, simulation-guided “vanilla and sprinkles” framework, i.e. from a basic to a more complex design, for designing platform trials. We addressed the functionality limitations of existing software as well as the unavailability of the coding therein by developing a suite of open-source software to use in simulating platform trials based on the R programming language. To give some examples, the newly developed software supports simulating staggered entry of treatments throughout the trial, choosing different options for control data sharing, specifying different platform stopping rules and platform-level operating characteristics. The software we developed is available through open-source licensing to enable users to access and modify the code. The separate use of two of these software packages to implement the same platform design by independent teams obtained the same results. We provide a framework, as well as open-source software for the design and simulation of platform trials. The software tools provide the flexibility necessary to capture the complexity of platform trials.
- 17 January 2025
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 25 (1) , 1-11
Open AccessWhy and how should we simulate platform trials? Learnings from EU-PEARL
Platform trials are innovative clinical trials governed by a master protocol that allows for the evaluation of multiple investigational treatments that enter and leave the trial over time. Interest in platform trials has been steadily increasing over the last decade. Due to their highly adaptive nature, platform trials provide sufficient flexibility to customize important trial design aspects to the requirements of both the specific disease under investigation and the different stakeholders. The flexibility of platform trials, however, comes with complexities when designing such trials. In the past, we reviewed existing software for simulating clinical trials and found that none of them were suitable for simulating platform trials as they do not accommodate the design features and flexibility inherent to platform trials, such as staggered entry of treatments over time. We argued that simulation studies are crucial for the design of efficient platform trials. We developed and proposed an iterative, simulation-guided “vanilla and sprinkles” framework, i.e. from a basic to a more complex design, for designing platform trials. We addressed the functionality limitations of existing software as well as the unavailability of the coding therein by developing a suite of open-source software to use in simulating platform trials based on the R programming language. To give some examples, the newly developed software supports simulating staggered entry of treatments throughout the trial, choosing different options for control data sharing, specifying different platform stopping rules and platform-level operating characteristics. The software we developed is available through open-source licensing to enable users to access and modify the code. The separate use of two of these software packages to implement the same platform design by independent teams obtained the same results. We provide a framework, as well as open-source software for the design and simulation of platform trials. The software tools provide the flexibility necessary to capture the complexity of platform trials.
- Open Access
NCC: An R-package for analysis and simulation of platform trials with non-concurrent controls
- 3 March 2023
- Published by The R Foundation
NCC: Simulation and Analysis of Platform Trials with Non-Concurrent Controls
- 3 March 2023
- Published by The R Foundation
NCC: Simulation and Analysis of Platform Trials with Non-Concurrent Controls